CSL in development of blood-derived Covid-19 treatment

Biotechnology giant CSL has begun development of a blood-derived treatment for Covid-19, known as COVID-19 Immunoglobulin. The Melbourne company believes the product could be used to treat people seriously ill with the complications caused by the virus, particularly those whose illness is progressing towards the need for ventilation. The treatment will be derived from blood…

Beyond travel, a trans-Tasman bubble is an opportunity for Australia and NZ to reduce dependence on China

The COVID-19 crisis has thrown Australian and New Zealand businesses’ dependence on China into stark relief. With countries reportedly competing with and undercutting each other to secure desperately needed medical supplies from China, many are now waking up to their economic exposure to a single manufacturing giant.

A new deal plan for manufacturing – SME leaders need to upskill too, by Scott Blakemore

The Australian Manufacturing Forum and @AuManufacturing’s campaign to crowd source a new deal plan for manufacturing post Covid-19 has taken in a broad range of perspectives. Here Scott Blakemore looks at SME leadership, reminding us that manufacturers can do a better job of being better prepared for the future.

Archer in quantum deal with IBM

New materials technology developer Archer Materials has signed an agreement with computing giant IBM to advance their quantum computing ambitions. The company, which is progressing development of a quantum computing chip, has joined the global IBM Q Network as an ‘ecosystem partner’. Archer’s chip, known as the CQ qubit processor, will now utilise IBM’s open…